Schizophrenia for primary care providers: how to contribute to the care of a vulnerable patient population

The American Journal of Medicine
Mark VironOliver Freudenreich

Abstract

Patients with schizophrenia represent a vulnerable population with high medical needs that are often missed or undertreated. Primary care providers have the potential to reduce health disparities experienced by this population and make a substantial difference in the overall health of these patients. This review provides primary care providers with a general understanding of the psychiatric and medical issues specific to patients with schizophrenia and a clinically practical framework for engaging and assessing this vulnerable patient population and assisting them in achieving optimal health. Initial steps in this framework include conducting a focused medical evaluation of psychosis and connecting patients with untreated psychosis to psychiatric care as promptly as possible. Given the significant contribution of cardiovascular disease to morbidity and mortality in schizophrenia, a top priority of primary care for patients with schizophrenia should be cardiovascular disease prevention and treatment through regular risk factor screening, appropriate lifestyle interventions, and other indicated therapies.

References

Dec 16, 1998·The British Journal of Psychiatry : the Journal of Mental Science·E C Harris, B Barraclough
Jul 15, 1999·Psychological Medicine·S BrownC Thompson
Sep 9, 2000·Schizophrenia Research·U OsbyP Sparén
Jun 4, 2002·The American Journal of Psychiatry·Jason B LuomaJane L Pearson
Jan 30, 2004·Diabetes Care·UNKNOWN American Diabetes AssociationUNKNOWN North American Association for the Study of Obesity
Feb 26, 2004·Obesity Research·UNKNOWN American Diabetes AssociationUNKNOWN North American Association for the Study of Obesity
Mar 17, 2004·Social Psychiatry and Psychiatric Epidemiology·Vaughan J CarrJenny L Chapman
Aug 3, 2004·The American Journal of Psychiatry·Stephen R MarderSteven Shon
Sep 21, 2005·The New England Journal of Medicine·Jeffrey A LiebermanUNKNOWN Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Mar 7, 2006·General Hospital Psychiatry·Benjamin G Druss, Silke A von Esenwein
Aug 4, 2006·Psychiatry and Clinical Neurosciences·Alp UçokSahap Erkoç
Dec 1, 2006·Journal of Cardiopulmonary Rehabilitation·James H Stein, Patrick E McBride
Feb 19, 2008·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Christian DolderZachariah Deyo
May 16, 2008·Epidemiologic Reviews·John McGrathJoy Welham
Aug 14, 2008·Acta Psychiatrica Scandinavica·Simon JonesGraham Thornicroft
Nov 22, 2008·Schizophrenia Research·Steven L BatkiRebecca A Drayer
Jan 8, 2009·JAMA : the Journal of the American Medical Association·Steven A Schroeder
Jan 31, 2009·Acta Psychiatrica Scandinavica·S M StahlJ M Meyer
Jul 30, 2009·Neuropsychology Review·Barton W PalmerRobert K Heaton
Aug 19, 2009·Community Mental Health Journal·Amanda J WheelerEve Tsai
Aug 25, 2009·Lancet·Jim van Os, Shitij Kapur
Sep 11, 2009·CNS Drugs·Kayvon SalimiJeffrey A Lieberman
Feb 2, 2010·The British Journal of Psychiatry : the Journal of Mental Science·Steve BrownHazel Inskip
Mar 26, 2010·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Lawrence MaayanChristoph U Correll
Apr 7, 2010·Drug Design, Development and Therapy·Silvio CacciaAlessandro Nobili
Apr 29, 2010·Current Diabetes Reports·Mehrul HasnainAnand K Pandurangi
Aug 3, 2010·Psychiatric Services : a Journal of the American Psychiatric Association·Leopoldo J CabassaRoberto Lewis-Fernández
Nov 6, 2010·Psychosomatics·Mark J Viron, Theodore A Stern
Dec 24, 2010·Clinical Schizophrenia & Related Psychoses·Leslie Citrome
Feb 1, 2009·Early Intervention in Psychiatry·Oliver FreudenreichDonald C Goff

❮ Previous
Next ❯

Citations

Mar 15, 2013·Epilepsia·Naoto AdachiPerminder Sachdev
Sep 6, 2015·Current Psychiatry Reports·Rose JonesChristopher Fear
May 28, 2016·Journal of Clinical Nursing·Brenda HappellRobert Stanton
Mar 3, 2016·Global Qualitative Nursing Research·Stephanie B EwartRobert Stanton
Jul 5, 2017·The British Journal of General Practice : the Journal of the Royal College of General Practitioners·Christoph KronenbergRowena Jacobs
Jan 8, 2019·Harvard Review of Psychiatry·Margaret SpottswoodHsiang Huang
Nov 7, 2019·The American Journal of Forensic Medicine and Pathology·Daming SunLing Li
Sep 25, 2019·Indian Journal of Psychological Medicine·Pooja Patnaik Kuppili, Naresh Nebhinani
Feb 22, 2012·The American Journal of Medicine·W Victor R ViewegAnanda K Pandurangi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.